F8 and autoimmune thrombocytopenic purpura: In benign hematology, the advent of FcRn inhibitors, recycling of C5 antibodies, and FVIII-mimetic bispecifics has further expanded the reach of antibody therapeutics beyond oncology, improving outcomes in ITP, PNH, aHUS, and hemophilia A.